Distribution of D-3-aminoisobutyrate-pyruvate aminotransferase in the rat brain

BMC Neuroscience

Shu-ichi Ueno²  Seiji Matsuda³  Satoshi Tanimukai²  Ryuji Fukuhara¹  Yuta Yoshino²  Takashi Ishimaru²  Kiyohiro Yamazaki²  Yoko Mori²  Shinichiro Ochi²  Masao Abe² 

[1]Department of Neuropsychiatry, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University, 1-1-1, Honjo, Chuou-ku, Kumamoto, Kumamoto 860-8556, Japan

[2]Department of Neuropsychiatry, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 791-0295, Japan

[3]Department of Anatomy and Embryology, Neuroscience, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 791-0295, Japan

关键词: Immunohistochemistry;    Western blotting;    RT-PCR;    Asymmetric dimethylarginine;    D-3-aminoisobutyrate-pyruvate aminotransferase;   

Others  :  799395
DOI  :  10.1186/1471-2202-15-53

 received in 2013-09-10, accepted in 2014-04-04,  发布年份 2014

【 摘 要 】

Background

D-3-aminoisobutyrate, an intermediary product of thymine, is converted to 2-methyl-3-oxopropanoate using pyruvate as an amino acceptor by D-3-aminoisobutyrate-pyruvate aminotransferase (D-AIB AT; EC 2.6.1.40). A large amount of D-AIB AT is distributed in the kidney and liver; however, small amounts are found in the brain. Recently, D-AIB AT was reported to metabolize asymmetric dimethylarginine (ADMA) in vivo and was suggested to be an important enzyme for nitric oxide metabolism because ADMA is a competitive inhibitor for nitric oxide synthase. In this study, we examined the distribution of D-AIB AT in the rat brain further to understand its role. We measured D-AIB AT mRNA and protein expression using quantitative RT-PCR and Western blotting, and monitored its distribution using immunohistochemical staining.

Results

D-AIB AT was distributed throughout the brain, with high expression in the cortex and hippocampus. Immunohistochemical staining revealed that D-AIB AT was highly expressed in the retrosplenial cortex and in hippocampal neurons.

Conclusion

Our results suggest that D-AIB AT is distributed in the examined- just the regions and may play an important role there.

【 授权许可】

   
2014 Abe et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Ueno S, Morino H, Sano A, Kakimoto Y: Purification and characterization of D-3-aminoisobutyrate-pyruvate aminotransferase from rat liver. Biochim Biophys Acta 1990, 1033:169-175.
• [2]Tamaki N, Kaneko M, Mizota C, Kikugawa M, Fujimoto S: Purification, characterization and inhibition of D-3-aminoisobutyrate aminotransferase from the rat liver. Eur J Biochem 1990, 189:39-45.
• [3]Matsui-Lee IS, Muragaki Y, Ideguchi T, Hase T, Tsuji M, Oschima A, Okuno E: Molecular cloning and sequencing of a cDNA encoding alanine-glyoxylate aminotransferase 2 from rat kidney. Biochem 1995, 117:856-862.
• [4]Yanai J, Kakimoto Y, Tsujio T, Sano I: Genetic study of beta-aminoisobutyric acid excretion by Japanese. Am J Hum Genet 1969, 21:115-132.
• [5]Kakimoto Y, Taniguchi K, Sano I: D-β-aminoisobutyrate:pyruvate aminotransferase in mammalian liver and excretion ob b aminoisobutyrate in man. J Biol Chem 1969, 244:336-340.
• [6]Kakimoto Y, Armstrong MD: The preparation and isolation of D-(−)-beta-aminoisobutyric acid. J Biol Chem 1961, 236:3283-3286.
• [7]Yanai I, Benjamin H, Shmoish M, Chalifa-Caspi V, Shklar M, Ophir R, Bar-Even A, Horn-Saban S, Safran M, Domany E, Lancet D, Shmueli O: Genome-wide midrange transcription profiles reveal expression level relationships in human tissue specification. Bioinformatics 2005, 21(5):650-659.
• [8]Ogawa T, Kimoto M, Sasaoka K: Dimethylarginine:pyruvate aminotransferase in rats. Purification, properties, and identity with alanine:glyoxylate aminotransferase 2. J Biol Chem 1990, 265:20938-20945.
• [9]Martens-Lobenhoffer J, Rodionov RN, Drust A, Bode-Böger SM: Detection and quantification of α-keto-δ-(N (G), N (G)-dimethylguanidino) valeric acid: a metabolite of asymmetric dimethylarginine. Anal Biochem 2011, 419:234-240.
• [10]Rodionov RN, Murry DJ, Vaulman SF, Stevens JW, Lentz SR: Human Alanine-Glyoxylate Aminotransferase 2 Lowers Asymmetric Dimethylarginine and Protects from Inhibition of Nitric Oxide Production. J Biol Chem 2010, 285:5385-5391.
• [11]Toda N, Ayajiki K, Okamura T: Cerebral blood flow regulation by nitric oxide in neurological disorders. Can J Physiol Pharmacol 2009, 87:581-594.
• [12]Scriver CR, Perry TL: Disorders of omega-amino acids in free and peptide-linked forms. In The Metabolic Basis of Inherited Disease Vol. 1. Edited by Scriver CR, Beaudet AL, Sly WS, Valle D. New York: McGraw-Hill Press; 1989:pp 755-771.
• [13]Kotani K, Ueno S, Sano A, Kakimoto Y: Isolation and identification of methylarginines from bovine brain. J Neurochem 1992, 58:1127-1129.
• [14]Ueno S, Sano A, Kotani K, Kondoh K, Kakimoto Y: Distribution of free methylarginines in rat tissues and in the bovine brain. J Neurochem 1992, 59:2012-2016.
• [15]Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, Vallance P: Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999, 343:209-214.
• [16]Kayrak M, Bacaksiz A, Vatankulu MA, Ayhan SS, Taner A, Unlü A, Yazici M, Ulgen MS: Association between exaggerated blood pressure response to exercise and serum asymmetric dimethylarginine levels. Circ J 2010, 74:1135-1141.
• [17]Wilson Tang WH, Tong W, Shrestha K, Wang Z, Levison BS, Delfraino B, Hu B, Troughton RW, Klein AL, Hazen SL: Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. Eur Heart J 2008, 29:2506-2513.
• [18]Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992, 339:572-575.
• [19]Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, O'Hara B, Rossiter S, Anthony S, Madhani M, Selwood D, Smith C, Wojciak-Stothard B, Rudiger A, Stidwill R, McDonald NQ, Vallance P: Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 2007, 13:198-203.
• [20]Vogt BA, Vogt LJ, Farber NB: Cingulate cortex and models of disease. In The Rat Nervous System. 3rd edition. Edited by Paxinos G. U.S.A: Elservier; 2004:pp705-727.
• [21]Cooper BG, Mizumori SJY: Retrosplenial cortex inactivation selectively impairs navigation in darkness. Neuro Rep 1999, 10:625-630.
• [22]Pengas G, Williams G, Cabronero JA, Ash TJ, Hong Y, Garcia DI, Fryer T, Hodges J, Nestor J: The relationship of topographical memory performance to regional neurodegeneration in Alzheimer’s disease. Front Aging Neurosci 2012, 4:article 17.
• [23]Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE: Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997, 42:85-94.
• [24]Villain N, Desgranges B, Viader F, de la Sayette V, MVzenge F, Landeau B, Baron JC, Eustache FC, Eust G: Relationships between hippocampal atrophy, white matter disruption, and gray matter hypometabolism in Alzheimer's disease. J Neurosci 2008, 28:6174-6181.
• [25]Vann SD, Aggleton JP, Maguire EA: What does the retrosplenial cortex do? Nat Rev Neurosci 2009, 10(11):792-802.